Koers VG Life Sciences Inc. Other OTC
Aandelen
VGLS
US91822T1016
Biotechnologie & Medisch Onderzoek
Omzet 2013 | - | Omzet 2014 | - | Marktkapitalisatie | 2,23 mln. 2,05 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2013 | -7 mln. -6,45 mln. | Nettowinst (verlies) 2014 | -6 mln. -5,53 mln. | EV/omzet 2013 | - |
Nettoschuld 2013 | 2,49 mln. 2,3 mln. | Nettoschuld 2014 | 3,83 mln. 3,52 mln. | EV/omzet 2014 | - |
K/w-verhouding 2013 |
-0,25
x | K/w-verhouding 2014 |
-0,31
x | Werknemers | - |
Dividendrendement 2013 * |
-
| Dividendrendement 2014 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paul Stricklandd
BRD | Director/Board Member | 48 | 01-01-17 |
Ana Gois
IRC | Investor Relations Contact | - | - |
Corporate Officer/Principal | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul Stricklandd
BRD | Director/Board Member | 48 | 01-01-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+67,53% | 63,85 mld. | |
-0,77% | 41,83 mld. | |
+44,98% | 40,65 mld. | |
-10,87% | 27,12 mld. | |
+13,30% | 26,52 mld. | |
-22,79% | 18,69 mld. | |
+4,70% | 12,73 mld. | |
+24,10% | 12,11 mld. | |
+27,41% | 12,07 mld. |